Serban San-Marina
Mayo Clinic, USA
Scientific Tracks Abstracts: J Stem Cell Res Ther
In spite of extraordinary recent progress in stem cell research, the replacement of tissues of the human body is currently unachievable with existing protocols. Furthermore, the need to replace damaged tissue and organs compel the development of technologies poised for early adoption that are sufficiently flexible to accommodate a personalized/precision approach. The current innovation deficit is due in part to limited choices of starting materials, incomplete knowledge of the factors affecting lineage commitments and limitations in gene delivery systems. To enable faster â??go/no goâ?? testing of new hypotheses, there is a need to increase reprogramming efficiency. We are addressing the issue or restoring organ functionality using small moleculeassisted protein reprogramming and stress-resistant pluripotent stem cells. To enable efficient reprogramming, small molecule process boosters are identified by zebrafish (zf)-assisted screening of compound libraries, including FDA-approved drugs that can be rapidly re-purposed. To illustrate the transforming potential of this technology we have selected as an end point, the regeneration of hair-like cells in the cochlea.
Serban San-Marina has completed his undergraduate and graduate studies at the University of Toronto, Medical studies at the Carol Davila School of Medicine and holds a PhD in Biology from York University. He has completed his Post-doctoral fellowships at Penn State in T-cell Immunobiology and at the Ontario Cancer Institute in Leukemia Transcription Factor Research. In 2006, he has co-founded Biostatistix for repurposed drug discovery. He has joined the Mayo Clinic in 2013 where his interests are in small molecule-directed stem cell reprogramming for regenerative medicine.
Email: SanMarina.Serban@Mayo.edu